Morepen Secures ₹500 Million Loan from Kookmin Bank to Fuel Expansion

Morepen Laboratories Ltd, a leading Indian pharmaceutical and medical device company, has approved a ₹500 million loan from Kookmin Bank, South Korea. This strategic funding is expected to bolster Morepen’s manufacturing capabilities, R&D initiatives, and export infrastructure, aligning with its aggressive growth trajectory in FY26.

Key Highlights:
Loan Approval: ₹500 million sanctioned by Kookmin Bank to support expansion and working capital needs.

Global Partnership: The deal strengthens Morepen’s international banking relationships and reflects confidence in its financial health.

Growth Strategy: Funds will be deployed toward scaling medical device production, especially glucometers and diagnostic kits.

Q2 Performance: PAT surged 64% YoY to ₹350 million; EBITDA rose 33% to ₹490 million.

Export Momentum: Exports grew 20% in H1 FY26, driven by demand in Asia and Africa.

Operational Scale: Installed base of glucometers crossed 13 million units; 22.1 million test strips sold.

This loan marks a pivotal step in Morepen’s journey toward becoming a global medtech and pharma powerhouse.

Sources: 1. Yahoo Finance – Morepen Q2 Earnings Highlights 2. Business Standard – Morepen Loan Approval Coverage